A practical reference on nitric oxide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Abiogenesis or the origin of life (sometimes called biopoiesis) is the natural process by which life arises from non-living matter, such as simple organic compounds. The prevailing scientific hypothesis is that the transition from non-living to living entities on Earth was not a single event, but a process of increasing complexity involving the formation of a habitable planet, the prebiotic synthesis of organic molecules, molecular self-replication, self-assembly, autocatalysis, and the emergence of cell membranes. The transition from non-life to life has not been observed experimentally, but many proposals have been made for different stages of the process. The study of abiogenesis aims to determine how pre-life chemical reactions gave rise to life under conditions strikingly different from those on Earth today. It uses tools from biology and chemistry, attempting a synthesis of many sciences. Life functions through the chemistry of carbon and water, and builds on four chemical families: lipids for cell membranes, carbohydrates for chemical energy storage and structural composition, amino acids for protein metabolism, and the nucleic acids DNA and RNA for heredity. A theory of abiogenesis must explain the origins and interactions of these classes of molecules. Many approaches investigate how self-replicating molecules came into existence. Researchers think that life descends from an RNA world, although other self-replicating and self-catalyzing molecules may have preceded RNA.
Areas of severe narrowing, stenosis, detectable by angiography, and to a lesser extent "stress testing" have long been the focus of human diagnostic techniques for cardiovascular disease, in general. However, these methods focus on detecting only severe narrowing, not the underlying atherosclerotic disease. As demonstrated by human clinical studies, most severe events occur in locations with heavy plaque, yet little or no lumen narrowing present before debilitating events suddenly occur. Plaque rupture can lead to artery lumen occlusion within seconds to minutes, potentially permanent disability, and sometimes sudden death. Plaques that have ruptured are known as complicated lesions. The extracellular matrix of the lesion breaks, usually at the shoulder of the fibrous cap that separates the lesion from the arterial lumen, where the exposed thrombogenic components of the plaque, mainly collagen, will trigger thrombus formation. The thrombus then travels downstream to other blood vessels, where the blood clot may partially or completely block blood flow. If the blood flow is completely blocked, cell death occurs due to the lack of oxygen supply to nearby cells, resulting in necrosis. The narrowing or obstruction of blood flow can occur in any artery within the body. Obstruction of arteries supplying the heart muscle results in a heart attack, while the obstruction of arteries supplying the brain results in an ischaemic stroke.
Penicillins (P, PCN or PEN) are a group of β-lactam antibiotics originally obtained from Penicillium moulds, principally P. chrysogenum and P. rubens. Eight species of Penicillium, in the section Chrysogena, produce penicillins. Most penicillins in clinical use are synthesised by P. chrysogenum using deep tank fermentation and then purified. A number of natural penicillins have been discovered, but only two purified compounds are in clinical use: penicillin G (intramuscular or intravenous use) and penicillin V (given by mouth). Penicillins were among the first medications to be effective against many bacterial infections caused by staphylococci and streptococci. They are still widely used today for various bacterial infections, though many types of bacteria have developed resistance following extensive use. In the United States, 10% of the population claims penicillin allergies, but because the frequency of positive skin test results decreases by 10% with each year of avoidance, 90% of these patients can eventually tolerate penicillin. Additionally, those with penicillin allergies can usually tolerate cephalosporins (another group of β-lactam) because the immunoglobulin E (IgE) cross-reactivity is only 3%. Penicillin was discovered in 1928 by the Scottish physician Alexander Fleming as a crude extract of P. rubens. Fleming's student Cecil George Paine was the first to successfully use penicillin to treat eye infection (neonatal conjunctivitis) in 1930.
Sources: en.wikipedia.org
== Used carrier proteins == Keyhole limpet hemocyanin It is copper-containing respiratory protein, isolated from keyhole limpets (Megathura crenulata). Because of its evolutionary distance from mammals, high molecular weight and complex structure it is usually immunogenic in vertebrate animals. Concholepas concholepas hemocyanin (also blue carrier immunogenic orotein) It is alternative to KLH isolated from Concholepas concholepas. It has the similar immunogenic properties as KLH but better solubility and therefore better flexibility. Bovine serum albumin It is from the blood sera of cows and has similarly immunogenic properties as KLH or CCH. The cationized form of BSA (cBSA) is highly positively charged protein with significantly increased immunogenicity. This change possesses a greater number of possible conjugated antigens to the protein. Ovalbumin Also known as egg albumin, OVA is the main protein (60-75%) found in hen egg white. OVA is soluble in dimethyl sulfoxide (DMSO), which enables the conjugation of haptens that are not soluble in aqueous buffers. The immune response can be enhanced using an adjuvant injected together with the immunogen.
Following the invasion, it formed part of Task Force Black/Knight to combat the post invasion insurgency; in late 2005/early 2006, the SAS were integrated into JSOC and focused its counterinsurgency efforts on combating al-Qaeda in Iraq and the Sunni insurgency alongside Delta Force. The counter-insurgency was successful, and the UKSF mission in Iraq ended in May 2009. Overall, more than 3,500 terrorists were "taken off the streets" of Baghdad by 22 SAS. Various British newspapers have speculated on SAS involvement in Operation Ellamy and the 2011 Libyan civil war. The Daily Telegraph reports that "defence sources have confirmed that the SAS has been in Libya for several weeks, and played a key role in coordinating the fall of Tripoli." While The Guardian reports "They have been acting as forward air controllers – directing pilots to targets – and communicating with NATO operational commanders. They have also been advising rebels on tactics." Members of the Special Air Service were deployed to Northern Iraq in late August 2014, and according to former SIS chief Richard Barrett, would also be sent to Syria, tasked with trying to track down the Islamic State of Iraq and the Levant (ISIL) terrorist group that the press labelled the Beatles. Since the 1990s SAS officers have risen to senior appointments in the British Armed Forces. General Peter de la Billière was the commander in chief of the British forces in the 1990 Gulf War. General Michael Rose became commander of the United Nations Protection Force in Bosnia in 1994.
== Poisoning == The prognosis is good for paracetamol overdoses if treatment is initiated up to 8 hours after the drug has been taken. Most hospitals stock the antidote (acetylcysteine), which replenishes the liver's supply of glutathione, allowing the NAPQI to be metabolized safely. Without early administration of the antidote, fulminant liver failure follows, often in combination with kidney failure, and death generally occurs within several days.
Coiled-coil drug delivery systems refer to drug delivery systems utilizing coiled-coil motifs capable of delivering disease-treating therapies, imaging agents, and vaccines to patients systemically or specifically. These systems are a form of peptide therapeutics and are capable of being engineered and finely tuned into different types of drug delivery vehicles (such as liposomes, nanoparticle drug carriers, polymer hybrid drug carriers, micelles, etc.) based on the specific application required. The goal of a coiled-coil drug delivery system is to deliver cargo such as medication, imaging agents, biological molecules, or vaccines efficiently and specifically, in order to maximize the therapeutic efficacy and minimize unwanted side effects. This is achieved through fine-tuning the factors affecting the coiled coil's oligomerization, resulting in modular systems that are highly specific for the intended application. Coiled-coil motifs make up 10% of all protein sequences, and are utilized naturally by various proteins in both prokaryotes and eukaryotes to achieve diverse cellular functions. Coupled with the simple helical structure of coiled coils which has been widely studied and reported on in literature, engineered coiled coil drug delivery systems are capable of improving drug pharmacokinetics, reducing unintentional toxicity during delivery, delivering drugs in a specific manner, controlling cargo release, and maintaining high stability through transport in the body.
Sources: en.wikipedia.org
The company also sponsored a complaint to the FDA, expressing concern that buprenorphine/naloxone sublingual tablets (the very product they formerly produced) were unsafe, requesting that applications for regulatory approval of generic products by other pharmaceutical companies (their competitors) be rejected by the US Food and Drug Administration.
Opioids agonists can also reduce the secretion of peptides by increasing the sympathetic nervous system through the μ-receptors in the ENS, which can lead to drier and harder stool. PAMORAs work against it so the stool becomes softer and less dry. PAMORAs effect on the function of the sphincter is in theory to regulate the movement coordination. The antagonist can prevent sphincter of Oddi dysfunction that is caused by opioids. Antagonists can also reduce opioid-induced anal sphincter dysfunction. The dysfunction is tied to straining, hemorrhoids and incomplete emptying.
The four substrates of this enzyme are indole-3-pyruvic acid, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are indole-3-acetic acid, oxidised NADP+, water, and carbon dioxide. The starting material is produced from the amino acid, tryptophan, by action of the enzyme L-tryptophan—pyruvate aminotransferase. The product of the reaction is the main auxin plant hormone.
The proprioceptive sense can be sharpened through study of many disciplines. Standing on a wobble board or balance board is often used to retrain or increase proprioceptive abilities, particularly as physical therapy for ankle or knee injuries. Slacklining is another method to increase proprioception. Standing on one leg (stork standing) and various other body-position challenges are also used in such disciplines as yoga, Wing Chun and tai chi. The vestibular system of the inner ear, vision and proprioception are the main three requirements for balance. Moreover, there are specific devices designed for proprioception training, such as the exercise ball, which works on balancing the abdominal and back muscles.
All four simple nitrogen trihalides are known. A few mixed halides and hydrohalides are known, but are mostly unstable; examples include NClF2, NCl2F, NBrF2, NF2H, NFH2, NCl2H, and NClH2. Nitrogen trifluoride (NF3, first prepared in 1928) is a colourless and odourless gas that is thermodynamically stable, and most readily produced by the electrolysis of molten ammonium fluoride dissolved in anhydrous hydrogen fluoride. Like carbon tetrafluoride, it is not at all reactive and is stable in water or dilute aqueous acids or alkalis. Only when heated does it act as a fluorinating agent, and it reacts with copper, arsenic, antimony, and bismuth on contact at high temperatures to give tetrafluorohydrazine (N2F4). The cations NF+4 and N2F+3 are also known (the latter from reacting tetrafluorohydrazine with strong fluoride-acceptors such as arsenic pentafluoride), as is ONF3, which has aroused interest due to the short N–O distance implying partial double bonding and the highly polar and long N–F bond. Tetrafluorohydrazine, unlike hydrazine itself, can dissociate at room temperature and above to give the radical NF2•. Fluorine azide (FN3) is very explosive and thermally unstable. Dinitrogen difluoride (N2F2) exists as thermally interconvertible cis and trans isomers, and was first found as a product of the thermal decomposition of FN3. Nitrogen trichloride (NCl3) is a dense, volatile, and explosive liquid whose physical properties are similar to those of carbon tetrachloride, although one difference is that NCl3 is easily hydrolysed by water while CCl4 is not.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.